Pregabalin efficacy in seizure disorders
Pro Research Analysisby 
Searched over 200M research papers
Pregabalin Efficacy in Partial (Focal) Seizure Disorders
Adjunctive Therapy for Partial Seizures: Efficacy and Dose-Response
Pregabalin has been shown to be effective as an add-on (adjunctive) therapy for patients with partial (focal) seizures, including those with or without secondary generalization. Multiple randomized, placebo-controlled trials and meta-analyses have demonstrated that pregabalin, at doses ranging from 150 to 600 mg per day, significantly reduces seizure frequency compared to placebo, with a clear dose-response relationship—higher doses generally lead to greater seizure reduction and higher responder rates (≥50% reduction in seizure frequency) 1235. Efficacy is apparent as early as the first week of treatment, and both twice-daily and three-times-daily dosing regimens are similarly effective 25.
Efficacy in Pediatric Patients with Focal Onset Seizures
In children aged 4–16 years with focal onset seizures, pregabalin at 10 mg/kg/day significantly reduced seizure frequency and increased responder rates compared to placebo. Lower doses showed numerical but not statistically significant improvements. The medication was generally well tolerated in pediatric populations .
Monotherapy for Partial Seizures: Comparison with Other Antiepileptic Drugs
Pregabalin has also been studied as monotherapy for partial-onset seizures. In one study, pregabalin monotherapy (600 mg/day) was effective and safe for patients with inadequately controlled partial-onset seizures, with a significant proportion of patients remaining seizure-free during the study period . However, when compared directly to lamotrigine in newly diagnosed partial seizures, pregabalin was found to have inferior efficacy, with fewer patients achieving six months of seizure freedom and a higher rate of withdrawal due to inadequate seizure control 68. Tolerability was similar between pregabalin and lamotrigine, but pregabalin was associated with more somnolence, weight gain, and convulsions 68.
Pregabalin vs. Gabapentin for Partial Seizures
When compared to gabapentin as adjunctive therapy for refractory partial-onset seizures, pregabalin did not show a significant difference in efficacy or safety. Both drugs had similar effects on seizure reduction, and their safety profiles were comparable .
Pregabalin in Generalized Tonic-Clonic Seizures
While animal models suggested potential efficacy for generalized tonic-clonic seizures, clinical evidence for pregabalin in this seizure type is limited. One recent trial specifically evaluated pregabalin for generalized tonic-clonic seizures in adults and children, but the abstract does not provide detailed efficacy results . Additionally, systematic reviews have noted a lack of data to support pregabalin use in generalized-onset tonic-clonic seizures .
Safety and Tolerability
Across studies, pregabalin is generally well tolerated, with the most common side effects being dizziness, somnolence, ataxia, and weight gain. Adverse events are dose-dependent and usually mild to moderate in intensity. Discontinuation rates due to adverse events increase at higher doses 1234+2 MORE.
Conclusion
Pregabalin is an effective and generally well-tolerated adjunctive therapy for partial (focal) seizures in both adults and children, with a clear dose-response relationship. As monotherapy, pregabalin is less effective than lamotrigine for newly diagnosed partial seizures. Its efficacy for generalized tonic-clonic seizures remains unclear due to limited data. Overall, pregabalin is a valuable option for patients with partial seizures, especially as adjunctive treatment, but may not be the first choice for monotherapy or for generalized seizure types.
Sources and full results
Most relevant research papers on this topic